Lannett Company, Inc. / UCB S.A. (Kremers Urban Pharmaceuticals Inc.)
2015 · Acquisition/Merger · $1.2B · Complete
Announcement Sentiment
67
Positive
Lannett acquired UCB's US specialty generics business Kremers Urban for approximately $1.23B in cash plus contingent payments, expanding into specialty generics including methylphenidate ER for ADHD. Closed November 27, 2015.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 10yr post-close.
Key facts
AnnouncedSep 02, 2015
ClosedNov 27, 2015
Deal value$1.2B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (ADHD, GERD, others)
IndicationsMultiple (ADHD, GERD, others)
Key assetsGeneric methylphenidate ER (ADHD), generic omeprazole ER, niche generics portfolio (18 marketed products)